Colimet

Colimet is a polymyxin-class antibiotic used for treating severe infections caused by multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae.
It is widely trusted in ICU and critical care setups for combating infections unresponsive to other antibiotics.

• Resistant Pathogen Coverage – Active against MDR & XDR Gram-negative strains
• Critical Care Utility – Ideal for life-threatening hospital-acquired infections
• High Potency – Restores bacterial sensitivity in complex cases
• Reliable Safety – Controlled nephrotoxicity with monitored use

Colistimethate Sodium, a prodrug of colistin, acts by disrupting the bacterial cell membrane, causing leakage of cellular contents and death of the organism.
It targets Gram-negative bacteria including carbapenem-resistant strains, making it invaluable in the management of hospital-acquired and ventilator-associated infections.

• Effective Against MDR/XDR Bacteria: Especially Pseudomonas, Acinetobacter, and Klebsiella.

• Fast-Acting Bactericidal Effect: Ensures prompt clinical response.

• Critical Care Essential: Trusted in ICUs and tertiary hospitals.

• Synergistic Potential: Can be used with carbapenems or tigecycline for resistant infections.

Colimet is indicated for serious infections caused by susceptible Gram-negative organisms, including:

• Hospital-acquired pneumonia (HAP/VAP)

• Bacteremia and sepsis

• Urinary tract infections

• Intra-abdominal infections

• Skin and soft tissue infections

• Bone and joint infections

• Meningitis due to MDR Gram-negative bacteria

• Use with caution in patients with renal impairment — dose adjustments are essential.

• Monitor renal and neurological functions during prolonged therapy.

• Avoid concomitant use with other nephrotoxic or neurotoxic drugs (e.g., aminoglycosides, vancomycin).

• Use only in confirmed or suspected MDR infections to prevent resistance development.

• Administer slowly by IV infusion to reduce the risk of respiratory muscle weakness.

• Discontinue immediately if neurological symptoms (e.g., tingling, confusion, or muscle weakness) occur.

• Not recommended for patients with known hypersensitivity to polymyxins.

Mild nausea, dizziness, or local pain at the injection site.
Occasionally, nephrotoxicity or mild neurotoxicity (headache, tingling, or confusion).
Rarely, allergic reactions, respiratory difficulty, or muscle weakness with high or prolonged dosing.

• Adults: 2.5–5 mg/kg/day (colistin base activity) divided every 8–12 hours via IV infusion.

• Route: Intravenous (IV) infusion or intramuscular (IM) injection.

• Reconstitution: Dissolve in sterile water for injection or 0.9% saline solution before administration.

• Renal Adjustment: Dosage should be reduced in patients with renal impairment.

• Administer only under strict medical supervision.